, a leader in the research and development of exosome-based therapies, plays a crucial role in Q Biomed’s technological advancements. Their cutting-edge research papers form the foundation of our innovative medical solutions, allowing us to integrate the latest scientific insights into our treatments. As a partner, CK-EXOGENE provides us with invaluable knowledge in exosome production, stem cell therapy, and regenerative medicine, making it possible for us to offer groundbreaking treatments for a wide range of conditions.
Here are some notable research papers from CK-EXOGENE that contribute to the development of Q Biomed’s medical technologies:
This paper explores the role of apoptotic cell-derived exosomes in cellular communication, which can be applied in targeted therapies for regenerative medicine and chronic disease treatments.
This review investigates the potential of exosomes in vaccine development, contributing to the broader field of immune response therapies.
This paper discusses how stem cell-derived exosomes can be used to treat osteoarthritis, a critical area of focus for Q Biomed’s Q JointRenew therapy.
This study looks into various methods for assessing scar formation and healing, which is relevant for Q ExoSkin Radiance, our aesthetic exosome solution.
Focusing on cancer therapy, this paper outlines how exosomes can be used to deliver therapeutic agents, highlighting the versatile applications of exosomes in various disease treatments.
The paper demonstrates how exosomes derived from dermal fibroblasts can be used to treat skin conditions like atopic dermatitis, reinforcing the scientific basis for Q ExoSkin Radiance
This research investigates the role of Gasdermin E in the biogenesis of apoptotic cell-derived exosomes, offering deeper insights into the molecular mechanisms that support exosome-based therapies.
This call for papers further emphasizes the potential of exosome-based therapies in oncology, an area where CK-EXOGENE continues to make significant contributions.
CK-EXOGENE holds numerous patents for the development of exosome-based technologies and production methods. These patents cover a wide range of innovations, from exosome production and applications to specific therapies targeting chronic diseases and cancers, which are integral to Q Biomed’s products, including the development and production of our MSC and exosome-based therapies.
2022 Thailand 2201007536 Method for preparing mesenchymal stem cell-derived exosome and culture solution produced from the same
CK-EXOGENE’s intellectual property is pivotal in shaping the future of exosome-based treatments, and their continued innovations are a major factor in the ongoing success of Q Biomed’s medical technologies.
Ongoing Developments
CK-EXOGENE is also at the forefront of developing exosome-based vaccines for shingles, flu, and AIDS, with promising progress in these areas. These ongoing developments further highlight the expanding potential of exosome therapies and their broad applications in both therapeutic and preventive medicine.
Through our partnership with CK-EXOGENE, Q Biomed is committed to bringing the most advanced, scientifically validated treatments to our patients, paving the way for better health outcomes in a wide range of medical conditions.
